AKT1 and lung adenocarcinoma: Combining baicalein with cisplatin has been shown to significantly attenuate cisplatin resistance in human A549 lung adenocarcinoma cells through inhibition of the PI3K/AKT/NF-κB pathway (Yu et al., 2017).